Loading...
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
BACKGROUND: Immune checkpoint inhibition (ICI) with anti-CTLA-4 and/or anti-PD-1 antibodies is standard treatment for metastatic melanoma. Anti-PD-1 (pembrolizumab, nivolumab) and anti-PD-L1 antibodies (atezolizumab, durvalumab, and avelumab) have been approved for treatment of several other advance...
Na minha lista:
| Udgivet i: | Front Immunol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6031714/ https://ncbi.nlm.nih.gov/pubmed/30002656 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01474 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|